Proof of Concept Studies

CRST uses scientific expertise to support your company’s go/no-go decisions by providing important and clinically relevant information on the behaviour of your drug candidate.

We are specialized in Phase I-II clinical trials that employ imaging and other biomarkers as surrogate endpoints. Turku PET Centre provides access to the latest developments in clinical and preclinical imaging technology.

Examples and success stories of the utilization of PET imaging in clinical drug development are available in 'downloads' below.

Strengths to facilitate Proof of Concept projects

CRST can offer efficient and comprehensive services for proof-of-concept studies because of its strengths that include:

PET imaging that provides a unique approach to obtain important clinical information on pharmacokinetics, target engagement and pharmacodynamics, especially in therapy areas such as CNS, cardiovascular and metabolic disorders.

Development and validation of novel biomarkers.

Flexible collaboration with Turku University Hospital in ensuring subject safety.

On-line pharmacokinetic analysis to support adaptive study designs.


Focus on PET and cardiovascular and metabolic imaging

Focus on PET and CNS disorders